## **Core Concept**
Myxoedema coma is a life-threatening complication of severe hypothyroidism. It is characterized by decreased mental status, hypothermia, and decreased reflexes. The condition requires immediate treatment to prevent mortality.

## **Why the Correct Answer is Right**
The correct approach to treating myxoedema coma involves supportive care and thyroid hormone replacement. The primary treatment includes administering thyroid hormones, specifically **T4 (levothyroxine)** and sometimes **T3 (liothyronine)**, along with supportive measures like warming, hydration, and treatment of any co-existing infections. Glucocorticoids are also often given to prevent potential adrenal crisis.

## **Why Each Wrong Option is Incorrect**
- **Option A:** While supportive care is crucial, the specifics of treatment, such as the type of thyroid hormone replacement, are critical. Simply providing general supportive care without thyroid hormone replacement would be insufficient.
- **Option B:** This option might seem plausible because hydration and warming are part of supportive care. However, without thyroid hormone replacement, these measures alone are not enough to treat the underlying cause of myxoedema coma.
- **Option C:** Administering glucocorticoids can be part of the treatment to prevent adrenal crisis but is not the sole treatment for myxoedema coma.

## **Clinical Pearl / High-Yield Fact**
A key point to remember is that in myxoedema coma, **T4 (levothyroxine)** is usually the preferred thyroid hormone for replacement therapy, and it should be given intravenously in this acute setting. Oral therapy may not be suitable due to potential gastrointestinal impairment.

## **Correct Answer:** . Intravenous T4 (levothyroxine) and supportive care.